Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?Zacks Investment Research • 04/14/22
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood DisorderBenzinga • 04/08/22
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack RatesBenzinga • 02/24/22
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)GlobeNewsWire • 02/24/22
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/23/22
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/23/22
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 02/23/22
Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst PharmaceuticalsSeeking Alpha • 02/07/22
BioCryst Pharmaceuticals: Updates To Thesis, Clinical And Commercial Momentum AcceleratingSeeking Alpha • 02/03/22
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewsWire • 02/01/22